IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy
RJJ Van Neerven, EF Knol, A Ejrnaes… - International archives of …, 2006 - karger.com
RJJ Van Neerven, EF Knol, A Ejrnaes, PA Würtzen
International archives of allergy and immunology, 2006•karger.comIt is well established that both the production of IgE by B lymphocytes and the maturation
and recruitment of eosinophils in late-phase reactions are dependent on the activation of
allergen-specific type-2 T-helper cells. What is less well known is the fact that efficient
activation of allergen-specific T cells upon low-dose exposure to allergens is critically
dependent on IgE-mediated or-facilitated allergen presentation. In fact, changes in the level
of IgE-mediated allergen presentation may account for many of the immunological effects …
and recruitment of eosinophils in late-phase reactions are dependent on the activation of
allergen-specific type-2 T-helper cells. What is less well known is the fact that efficient
activation of allergen-specific T cells upon low-dose exposure to allergens is critically
dependent on IgE-mediated or-facilitated allergen presentation. In fact, changes in the level
of IgE-mediated allergen presentation may account for many of the immunological effects …
Abstract
It is well established that both the production of IgE by B lymphocytes and the maturation and recruitment of eosinophils in late-phase reactions are dependent on the activation of allergen-specific type-2 T-helper cells. What is less well known is the fact that efficient activation of allergen-specific T cells upon low-dose exposure to allergens is critically dependent on IgE-mediated or -facilitated allergen presentation. In fact, changes in the level of IgE-mediated allergen presentation may account for many of the immunological effects described for specific immunotherapy or anti-IgE treatment. This review aims to summarize the current knowledge, and will discuss the clinical relevance of blocking IgG antibodies induced by specific immunotherapy and anti-IgE monoclonal antibodies that both interfere with IgE-mediated allergen presentation.
Karger